Studies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Bur

The Alzheimer's Immunotherapy Program (AIP) is a collaboration between Elan and Wyeth to research, develop, and commercialize immunotherapeutic approaches that may be used to treat and possibly prevent the onset of Alzheimer's disease. The AIP is committed to researching the burden of care and cost of AD as well as developing tools that help advance these efforts. The AIP is also currently conducting clinical trial enrollment throughout Europe and the United States for its lead investigative compound bapineuzumab.

An extensive global Phase 3 clinical program was initiated in December 2007 for bapineuzumab as a potential treatment for patients with mild to moderate Alzheimer's disease. To learn more about this trial and potential enrollment, patients or caregivers should contact clinical sites directly. Participating clinical sites in North America can be found by visiting www.icarastudy.com or calling 1-888-818-MEMORY. For study information outside North America, visit www.globalicarastudy.com. Study site details also can be found on www.clinicaltrials.gov. In addition, the AIP is continuing to conduct safety trials with bapineuzumab subcutaneous and ACC-001.

About Elan

Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York, London and Dublin Stock Exchanges. For additional information about the company, please visit http://www.elan.com.

About Wyeth

Wyeth (NYSE:WYE) is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

Safe Harbor/Forward-Looking Statements

The statements in this press release regarding the Alzheimer's Immunotherapy Program, including the clinical program for bapineuzumab, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In particular, there can be no assurance that the clinical program for bapineuzumab will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that bapineuzumab will ever receive regulatory approval or be successfully commercialized. Other risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these forward-looking statements include those detailed from time to time in the companies' periodic reports filed with the Securities and Exchange Commission, including Wyeth`s current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors" in Wyeth's Annual Report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on February 27, 2009, and Elan's Reports of Foreign Issuer on Form 6-K and Annual Report on Form 20-F, particularly the discussion under the caption "Item 3D, Risk Factors" in Elan's Annual Report on Form 20-F for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on February 26, 2009 The forward-looking statements in this press release are qualified by these risk factors. The companies assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

investors, Chris Burns, +1-800-252-3526, or David Marshall, +353-1-709-4444, both of Elan, or Justin Victoria, +1-973-660-5340 of Wyeth; media, Mary Stutts, +1-650-794-4403 or +1-650-823-5255, or Miriam Mason, +1-650-238-7113 or +1-650-877-7616, both of Elan, or Douglas Petkus, +1-973-660-5218, or Gwendolyn Fisher, +1-484-865-5160, both of Wyeth